They have been shown to have potential to treat tumours that express GPR30.24, 25 Due to the bidirectional nature of GPR30 on tumour growth, G15 limits the progression of non‐small cell lung cancer (NSCLC) by inhibiting GPR30 signalling.25 G1 inhibits the growth of prostate tumour cells in vivo and in vitro by activating GPR30 signalling.30 These studies suggest that targeting GPR30 may be a potential target for treating cancer more efficiently. This evidence concerns the gene GPER1 and non-small cell lung carcinoma.